
                                SEQUENCE LISTING

<110> Fred Hutchinson Cancer Research Center
      Salter, Alexander
      Riddell, Stanley

<120> CHIMERIC RECEPTOR PROTEINS AND USES THEREOF

<130> 360056.465WO

<140> PCT/US2019/052492
<141> 2019-09-23

<150> US 62/901,194
<151> 2019-09-16

<150> US 62/735,702
<151> 2018-09-24

<160> 111

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence ITAM motif

<220>
<221> VARIANT        
<222> (2)...(3)
<223> Xaa = any amino acid

<220>
<221> VARIANT        
<222> 4
<223> Xaa = L or I

<400> 1
Tyr Xaa Xaa Xaa
 1

<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence ITAM motif

<220>
<221> VARIANT        
<222> 2,3
<223> Xaa = any amino acid

<220>
<221> VARIANT        
<222> 4
<223> Xaa = L or I

<220>
<221> VARIANT
<222> (5)...(10)
<223> Xaa = any amino acid

<220>
<221> VARIANT        
<222> 11,12
<223> Any one of amino acids 11-12 can be either present
      or absent

<220>
<221> VARIANT        
<222> 14,15
<223> Xaa = any amino acid

<220>
<221> VARIANT        
<222> 16
<223> Xaa = L or I

<400> 2
Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa
 1               5                  10                  15

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence Lck-binding motif

<220>
<221> VARIANT        
<222> 3,4,6,7
<223> Xaa = any amino acid

<400> 3
Arg Lys Xaa Xaa Tyr Xaa Xaa Tyr
 1               5

<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence domain within CD3epsilon ITAM

<220>
<221> VARIANT        
<222> (3)...(8)
<223> Xaa = any amino acid

<400> 4
Arg Lys Xaa Xaa Xaa Xaa Xaa Xaa Tyr
 1               5

<210> 5
<211> 185
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3epsilon without signal
      peptide

<400> 5
Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys Val
 1               5                  10                  15
Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro Gly
            20                  25                  30
Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp Glu
        35                  40                  45
Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys Glu
    50                  55                  60
Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly
65                  70                  75                  80
Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg Val
                85                  90                  95
Cys Glu Asn Cys Met Glu Met Asp Val Met Ser Val Ala Thr Ile Val
            100                 105                 110
Ile Val Asp Ile Cys Ile Thr Gly Gly Leu Leu Leu Leu Val Tyr Tyr
        115                 120                 125
Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala
    130                 135                 140
Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro
145                 150                 155                 160
Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu
                165                 170                 175
Tyr Ser Gly Leu Asn Gln Arg Arg Ile
            180                 185

<210> 6
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3epsilon ITAM sequence

<400> 6
Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu
 1               5                  10                  15

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3epsilon PRS

<400> 7
Pro Pro Pro Val Pro Asn Pro
 1               5

<210> 8
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3epsilon fragment

<400> 8
Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln
 1               5                  10                  15
Arg Asp Leu Tyr Ser Gly Leu
            20

<210> 9
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3epsilon BRS

<400> 9
Lys Asn Arg Lys Ala Lys Ala Lys
 1               5

<210> 10
<211> 160
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3gamma without signal
      peptide

<400> 10
Gln Ser Ile Lys Gly Asn His Leu Val Lys Val Tyr Asp Tyr Gln Glu
 1               5                  10                  15
Asp Gly Ser Val Leu Leu Thr Cys Asp Ala Glu Ala Lys Asn Ile Thr
            20                  25                  30
Trp Phe Lys Asp Gly Lys Met Ile Gly Phe Leu Thr Glu Asp Lys Lys
        35                  40                  45
Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp Pro Arg Gly Met Tyr Gln
    50                  55                  60
Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro Leu Gln Val Tyr Tyr Arg
65                  70                  75                  80
Met Cys Gln Asn Cys Ile Glu Leu Asn Ala Ala Thr Ile Ser Gly Phe
                85                  90                  95
Leu Phe Ala Glu Ile Val Ser Ile Phe Val Leu Ala Val Gly Val Tyr
            100                 105                 110
Phe Ile Ala Gly Gln Asp Gly Val Arg Gln Ser Arg Ala Ser Asp Lys
        115                 120                 125
Gln Thr Leu Leu Pro Asn Asp Gln Leu Tyr Gln Pro Leu Lys Asp Arg
    130                 135                 140
Glu Asp Asp Gln Tyr Ser His Leu Gln Gly Asn Gln Leu Arg Arg Asn
145                 150                 155                 160

<210> 11
<211> 45
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3gamma cytoplasmic
      domain sequence

<400> 11
Gly Gln Asp Gly Val Arg Gln Ser Arg Ala Ser Asp Lys Gln Thr Leu
 1               5                  10                  15
Leu Pro Asn Asp Gln Leu Tyr Gln Pro Leu Lys Asp Arg Glu Asp Asp
            20                  25                  30
Gln Tyr Ser His Leu Gln Gly Asn Gln Leu Arg Arg Asn
        35                  40                  45

<210> 12
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3gamma ITAM sequence

<400> 12
Tyr Gln Pro Leu Lys Asp Arg Glu Asp Asp Gln Tyr Ser His Leu
 1               5                  10                  15

<210> 13
<211> 149
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3delta without signal
      peptide

<400> 13
Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg Val Phe Val Asn Cys Asn
 1               5                  10                  15
Thr Ser Ile Thr Trp Val Glu Gly Thr Val Gly Thr Leu Leu Ser Asp
            20                  25                  30
Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile Leu Asp Pro Arg Gly Ile
        35                  40                  45
Tyr Arg Cys Asn Gly Thr Asp Ile Tyr Lys Asp Lys Glu Ser Thr Val
    50                  55                  60
Gln Val His Tyr Arg Met Cys Gln Ser Cys Val Glu Leu Asp Pro Ala
65                  70                  75                  80
Thr Val Ala Gly Ile Ile Val Thr Asp Val Ile Ala Thr Leu Leu Leu
                85                  90                  95
Ala Leu Gly Val Phe Cys Phe Ala Gly His Glu Thr Gly Arg Leu Ser
            100                 105                 110
Gly Ala Ala Asp Thr Gln Ala Leu Leu Arg Asn Asp Gln Val Tyr Gln
        115                 120                 125
Pro Leu Arg Asp Arg Asp Asp Ala Gln Tyr Ser His Leu Gly Gly Asn
    130                 135                 140
Trp Ala Arg Asn Lys
145

<210> 14
<211> 45
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3delta cytoplasmic
      domain

<400> 14
Gly His Glu Thr Gly Arg Leu Ser Gly Ala Ala Asp Thr Gln Ala Leu
 1               5                  10                  15
Leu Arg Asn Asp Gln Val Tyr Gln Pro Leu Arg Asp Arg Asp Asp Ala
            20                  25                  30
Gln Tyr Ser His Leu Gly Gly Asn Trp Ala Arg Asn Lys
        35                  40                  45

<210> 15
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3delta ITAM sequence

<400> 15
Tyr Gln Pro Leu Arg Asp Arg Asp Asp Ala Gln Tyr Ser His Leu
 1               5                  10                  15

<210> 16
<211> 143
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3zeta without signal
      peptide

<400> 16
Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys Tyr Leu Leu Asp Gly
 1               5                  10                  15
Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu Arg Val
            20                  25                  30
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
        35                  40                  45
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
    50                  55                  60
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Gln
65                  70                  75                  80
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
                85                  90                  95
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
            100                 105                 110
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
        115                 120                 125
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
    130                 135                 140

<210> 17
<211> 113
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence human CD3zeta cytoplasmic
      domain

<400> 17
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 1               5                  10                  15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
            20                  25                  30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
        35                  40                  45
Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
    50                  55                  60
Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
65                  70                  75                  80
Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
                85                  90                  95
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
            100                 105                 110
Arg


<210> 18
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3zeta ITAM (a) sequence

<400> 18
Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
 1               5                  10                  15

<210> 19
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3zeta ITAM (b) sequence

<400> 19
Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile
 1               5                  10                  15

<210> 20
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3zeta ITAM (c) sequence

<400> 20
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
 1               5                  10                  15

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3zeta BRS (a) sequence

<400> 21
Lys Arg Arg Gly Arg
 1               5

<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3zeta BRS (b) sequence

<400> 22
Lys Pro Gln Arg Arg Lys
 1               5

<210> 23
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3zeta BRS (c) sequence

<400> 23
Lys Gly Glu Arg Arg Arg Gly Lys
 1               5

<210> 24
<211> 29
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic sequence comprising human CD3epsilon PRS
      and ITAM

<400> 24
Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly
 1               5                  10                  15
Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile
            20                  25

<210> 25
<211> 43
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human 4-1BB signaling sequence

<400> 25
Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
 1               5                  10                  15
Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
            20                  25                  30
Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
        35                  40

<210> 26
<211> 28
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD28 transmembrane sequence

<400> 26
Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
 1               5                  10                  15
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
            20                  25

<210> 27
<211> 167
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic CD3epsilon_CD3zeta sequence

<400> 27
Lys Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala Gly Ala
 1               5                  10                  15
Gly Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro Val Pro
            20                  25                  30
Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser
        35                  40                  45
Gly Leu Asn Gln Arg Arg Ile Arg Val Lys Phe Ser Arg Ser Ala Asp
    50                  55                  60
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
65                  70                  75                  80
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
                85                  90                  95
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
            100                 105                 110
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
        115                 120                 125
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
    130                 135                 140
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
145                 150                 155                 160
Met Gln Ala Leu Pro Pro Arg
                165

<210> 28
<211> 167
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic CD3zeta_CD3epsilon sequence

<400> 28
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 1               5                  10                  15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
            20                  25                  30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
        35                  40                  45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
    50                  55                  60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65                  70                  75                  80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
                85                  90                  95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
            100                 105                 110
Lys Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala Gly Ala
        115                 120                 125
Gly Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro Val Pro
    130                 135                 140
Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser
145                 150                 155                 160
Gly Leu Asn Gln Arg Arg Ile
                165

<210> 29
<211> 141
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic CD3epsilon_PRS_ITAM CD3zeta sequence

<400> 29
Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly
 1               5                  10                  15
Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile Arg Val Lys
            20                  25                  30
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
        35                  40                  45
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
    50                  55                  60
Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
65                  70                  75                  80
Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
                85                  90                  95
Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
            100                 105                 110
Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
        115                 120                 125
Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
    130                 135                 140

<210> 30
<211> 209
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 4-1BB_CD3epsilon_ CD3zeta sequence

<400> 30
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
 1               5                  10                  15
Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
            20                  25                  30
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Lys Asn Arg Lys Ala Lys
        35                  40                  45
Ala Lys Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg Gln Arg Gly
    50                  55                  60
Gln Asn Lys Glu Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro
65                  70                  75                  80
Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg
                85                  90                  95
Ile Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
            100                 105                 110
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
        115                 120                 125
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
    130                 135                 140
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
145                 150                 155                 160
Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
                165                 170                 175
Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
            180                 185                 190
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
        195                 200                 205
Arg


<210> 31
<211> 209
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 4-1BB_CD3zeta _ CD3epsilon sequence

<400> 31
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
 1               5                  10                  15
Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
            20                  25                  30
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg
        35                  40                  45
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
    50                  55                  60
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
65                  70                  75                  80
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
                85                  90                  95
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
            100                 105                 110
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
        115                 120                 125
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
    130                 135                 140
Ala Leu His Met Gln Ala Leu Pro Pro Arg Lys Asn Arg Lys Ala Lys
145                 150                 155                 160
Ala Lys Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg Gln Arg Gly
                165                 170                 175
Gln Asn Lys Glu Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro
            180                 185                 190
Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg
        195                 200                 205
Ile


<210> 32
<211> 183
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 4-1BB_CD3epsilon_PRS_ITAM CD3zeta
      sequence

<400> 32
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
 1               5                  10                  15
Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
            20                  25                  30
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Pro Pro Pro Val Pro
        35                  40                  45
Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser
    50                  55                  60
Gly Leu Asn Gln Arg Arg Ile Arg Val Lys Phe Ser Arg Ser Ala Asp
65                  70                  75                  80
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
                85                  90                  95
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
            100                 105                 110
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
        115                 120                 125
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
    130                 135                 140
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
145                 150                 155                 160
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
                165                 170                 175
Met Gln Ala Leu Pro Pro Arg
            180

<210> 33
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic IgG4 hinge sequence

<220>
<221> VARIANT        
<222> 10
<223> Xaa = P or S

<400> 33
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Xaa Cys Pro
 1               5                  10

<210> 34
<211> 165
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD3epsilon intracellular sequence

<400> 34
aagaaccgga aggccaaggc caagcctgtg acaagaggtg ctggtgctgg cggcagacag      60
agaggccaga acaaagaaag acctcctcct gtgcctaatc ctgactacga gcccatccgg     120
aagggccaga gagatctgta ctccggcctg aaccagcggc ggatt                     165

<210> 35
<211> 87
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD3epsilon_PRS_ITAM CD3zeta sequence

<400> 35
agacctcctc ctgtgcctaa tcctgactac gagcccatcc ggaagggcca gagagatctg      60
tactccggcc tgaaccagcg gcggatt                                          87

<210> 36
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD3zeta intracellular sequence

<400> 36
cgggtgaagt tcagcagaag cgccgacgcc cctgcctacc agcagggcca gaatcagctg      60
tacaacgagc tgaacctggg cagaagggaa gagtacgacg tcctggataa gcggagaggc     120
cgggaccctg agatgggcgg caagcctcgg cggaagaacc cccaggaagg cctgtataac     180
gaactgcaga aagacaagat ggccgaggcc tacagcgaga tcggcatgaa gggcgagcgg     240
aggcggggca agggccacga cggcctgtat cagggcctgt ccaccgccac caaggatacc     300
tacgacgccc tgcacatgca ggccctgccc ccaagg                               336

<210> 37
<211> 126
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic 4-1BB signaling sequence

<400> 37
aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa      60
actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt     120
gaactg                                                                126

<210> 38
<211> 84
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD28 transmembrane sequence

<400> 38
atgttctggg tgctggtggt ggtcggaggc gtgctggcct gctacagcct gctggtcacc      60
gtggccttca tcatcttttg ggtg                                             84

<210> 39
<211> 36
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic IgG4 hinge sequence

<400> 39
gagagcaagt acggaccgcc ctgcccccct tgccct                                36

<210> 40
<211> 633
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD28tm_4-1BB signal_CD3epsilon_PRS_ITAM
      CD3zeta sequence

<400> 40
atgttctggg tgctggtggt ggtcggaggc gtgctggcct gctacagcct gctggtcacc      60
gtggccttca tcatcttttg ggtgaaacgg ggcagaaaga aactcctgta tatattcaaa     120
caaccattta tgagaccagt acaaactact caagaggaag atggctgtag ctgccgattt     180
ccagaagaag aagaaggagg atgtgaactg agacctcctc ctgtgcctaa tcctgactac     240
gagcccatcc ggaagggcca gagagatctg tactccggcc tgaaccagcg gcggattcgg     300
gtgaagttca gcagaagcgc cgacgcccct gcctaccagc agggccagaa tcagctgtac     360
aacgagctga acctgggcag aagggaagag tacgacgtcc tggataagcg gagaggccgg     420
gaccctgaga tgggcggcaa gcctcggcgg aagaaccccc aggaaggcct gtataacgaa     480
ctgcagaaag acaagatggc cgaggcctac agcgagatcg gcatgaaggg cgagcggagg     540
cggggcaagg gccacgacgg cctgtatcag ggcctgtcca ccgccaccaa ggatacctac     600
gacgccctgc acatgcaggc cctgccccca agg                                  633

<210> 41
<211> 711
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD28tm_4-1BB signal_CD3epsilon_CD3zeta
      sequence

<400> 41
atgttctggg tgctggtggt ggtcggaggc gtgctggcct gctacagcct gctggtcacc      60
gtggccttca tcatcttttg ggtgaaacgg ggcagaaaga aactcctgta tatattcaaa     120
caaccattta tgagaccagt acaaactact caagaggaag atggctgtag ctgccgattt     180
ccagaagaag aagaaggagg atgtgaactg aagaaccgga aggccaaggc caagcctgtg     240
acaagaggtg ctggtgctgg cggcagacag agaggccaga acaaagaaag acctcctcct     300
gtgcctaatc ctgactacga gcccatccgg aagggccaga gagatctgta ctccggcctg     360
aaccagcggc ggattcgggt gaagttcagc agaagcgccg acgcccctgc ctaccagcag     420
ggccagaatc agctgtacaa cgagctgaac ctgggcagaa gggaagagta cgacgtcctg     480
gataagcgga gaggccggga ccctgagatg ggcggcaagc ctcggcggaa gaacccccag     540
gaaggcctgt ataacgaact gcagaaagac aagatggccg aggcctacag cgagatcggc     600
atgaagggcg agcggaggcg gggcaagggc cacgacggcc tgtatcaggg cctgtccacc     660
gccaccaagg atacctacga cgccctgcac atgcaggccc tgcccccaag g              711

<210> 42
<211> 711
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic CD28tm_4-1BB signal_CD3zeta_CD3epsilon
      sequence

<400> 42
atgttctggg tgctggtggt ggtcggaggc gtgctggcct gctacagcct gctggtcacc      60
gtggccttca tcatcttttg ggtgaaacgg ggcagaaaga aactcctgta tatattcaaa     120
caaccattta tgagaccagt acaaactact caagaggaag atggctgtag ctgccgattt     180
ccagaagaag aagaaggagg atgtgaactg cgggtgaagt tcagcagaag cgccgacgcc     240
cctgcctacc agcagggcca gaatcagctg tacaacgagc tgaacctggg cagaagggaa     300
gagtacgacg tcctggataa gcggagaggc cgggaccctg agatgggcgg caagcctcgg     360
cggaagaacc cccaggaagg cctgtataac gaactgcaga aagacaagat ggccgaggcc     420
tacagcgaga tcggcatgaa gggcgagcgg aggcggggca agggccacga cggcctgtat     480
cagggcctgt ccaccgccac caaggatacc tacgacgccc tgcacatgca ggccctgccc     540
ccaaggaaga accggaaggc caaggccaag cctgtgacaa gaggtgctgg tgctggcggc     600
agacagagag gccagaacaa agaaagacct cctcctgtgc ctaatcctga ctacgagccc     660
atccggaagg gccagagaga tctgtactcc ggcctgaacc agcggcggat t              711

<210> 43
<211> 2673
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic construct sequence: GM-CSF leader_FMC63
      scFv_STII_(G4S)2_IgG4
      hinge_CD28tm_4-1BB_CD3epsilon_PRS_ITAM
      CD3zeta_T2A_GM-CSF leader_tEGFR

<400> 43
atgctgctgc tggtgaccag cctgctgctg tgcgagctgc cccaccctgc ctttctgctg      60
atccccgaca tccagatgac ccagaccacc tccagcctga gcgccagcct gggcgaccgg     120
gtgaccatca gctgccgggc cagccaggac atcagcaagt acctgaactg gtatcagcag     180
aagcccgacg gcaccgtcaa gctgctgatc taccacacca gccggctgca cagcggcgtg     240
cctagccggt ttagcggcag cggctccggc accgactaca gcctgaccat ctccaacctg     300
gaacaggaag atatcgccac ctacttttgc cagcagggca acacactgcc ctacaccttt     360
ggcggcggaa caaagctgga aatcaccggc agcacctccg gcagcggcaa gcctggcagc     420
ggcgagggca gcaccaaggg cgaggtgaag ctgcaggaaa gcggccctgg cctggtggcc     480
cccagccaga gcctgagcgt gacctgcacc gtgagcggcg tgagcctgcc cgactacggc     540
gtgagctgga tcaggcagcc ccccaggaag ggcctggaat ggctgggcgt gatctggggc     600
agcgagacca cctactacaa cagcgccctg aagagccggc tgaccatcat caaggacaac     660
agcaagagcc aggtgttcct gaagatgaac agcctgcaga ccgacgacac cgccatctac     720
tactgcgcca agcactacta ctacggcggc agctacgcca tggactactg gggccagggc     780
accagcgtga ccgtgagcag caattggagc cacccgcagt tcgaaaaagg aggtggaggt     840
tcaggtggtg gaggctctga gagcaagtac ggaccgccct gccccccttg ccctatgttc     900
tgggtgctgg tggtggtcgg aggcgtgctg gcctgctaca gcctgctggt caccgtggcc     960
ttcatcatct tttgggtgaa acggggcaga aagaaactcc tgtatatatt caaacaacca    1020
tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa    1080
gaagaagaag gaggatgtga actgagacct cctcctgtgc ctaatcctga ctacgagccc    1140
atccggaagg gccagagaga tctgtactcc ggcctgaacc agcggcggat tcgggtgaag    1200
ttcagcagaa gcgccgacgc ccctgcctac cagcagggcc agaatcagct gtacaacgag    1260
ctgaacctgg gcagaaggga agagtacgac gtcctggata agcggagagg ccgggaccct    1320
gagatgggcg gcaagcctcg gcggaagaac ccccaggaag gcctgtataa cgaactgcag    1380
aaagacaaga tggccgaggc ctacagcgag atcggcatga agggcgagcg gaggcggggc    1440
aagggccacg acggcctgta tcagggcctg tccaccgcca ccaaggatac ctacgacgcc    1500
ctgcacatgc aggccctgcc cccaaggctc gagggcggcg gagagggcag aggaagtctt    1560
ctaacatgcg gtgacgtgga ggagaatccc ggccctagga tgcttctcct ggtgacaagc    1620
cttctgctct gtgagttacc acacccagca ttcctcctga tcccacgcaa agtgtgtaac    1680
ggaataggta ttggtgaatt taaagactca ctctccataa atgctacgaa tattaaacac    1740
ttcaaaaact gcacctccat cagtggcgat ctccacatcc tgccggtggc atttaggggt    1800
gactccttca cacatactcc tcctctggat ccacaggaac tggatattct gaaaaccgta    1860
aaggaaatca cagggttttt gctgattcag gcttggcctg aaaacaggac ggacctccat    1920
gcctttgaga acctagaaat catacgcggc aggaccaagc aacatggtca gttttctctt    1980
gcagtcgtca gcctgaacat aacatccttg ggattacgct ccctcaagga gataagtgat    2040
ggagatgtga taatttcagg aaacaaaaat ttgtgctatg caaatacaat aaactggaaa    2100
aaactgtttg ggacctccgg tcagaaaacc aaaattataa gcaacagagg tgaaaacagc    2160
tgcaaggcca caggccaggt ctgccatgcc ttgtgctccc ccgagggctg ctggggcccg    2220
gagcccaggg actgcgtctc ttgccggaat gtcagccgag gcagggaatg cgtggacaag    2280
tgcaaccttc tggagggtga gccaagggag tttgtggaga actctgagtg catacagtgc    2340
cacccagagt gcctgcctca ggccatgaac atcacctgca caggacgggg accagacaac    2400
tgtatccagt gtgcccacta cattgacggc ccccactgcg tcaagacctg cccggcagga    2460
gtcatgggag aaaacaacac cctggtctgg aagtacgcag acgccggcca tgtgtgccac    2520
ctgtgccatc caaactgcac ctacggatgc actgggccag gtcttgaagg ctgtccaacg    2580
aatgggccta agatcccgtc catcgccact gggatggtgg gggccctcct cttgctgctg    2640
gtggtggccc tggggatcgg cctcttcatg tga                                 2673

<210> 44
<211> 2682
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic construct sequence: GM-CSF leader_R12
      scFv_STII_(G4S)2_IgG4
      hinge_CD28tm_4-1BB_CD3epsilon_PRS_ITAM
      CD3zeta_T2A_GM-CSF leader_tEGFR

<400> 44
atgctgctgc tggtgacaag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atcccccagg aacagctcgt cgaaagcggc ggcagactgg tgacacctgg cggcagcctg     120
accctgagct gcaaggccag cggcttcgac ttcagcgcct actacatgag ctgggtccgc     180
caggcccctg gcaagggact ggaatggatc gccaccatct accccagcag cggcaagacc     240
tactacgcca cctgggtgaa cggacggttc accatctcca gcgacaacgc ccagaacacc     300
gtggacctgc agatgaacag cctgacagcc gccgaccggg ccacctactt ttgcgccaga     360
gacagctacg ccgacgacgg cgccctgttc aacatctggg gccctggcac cctggtgaca     420
atctctagcg gcggaggcgg atctggtggc ggaggaagtg gcggcggagg atctgagctg     480
gtgctgaccc agagcccctc tgtgtctgct gccctgggaa gccctgccaa gatcacctgt     540
accctgagca gcgcccacaa gaccgacacc atcgactggt atcagcagct gcagggcgag     600
gcccccagat acctgatgca ggtgcagagc gacggcagct acaccaagag gccaggcgtg     660
cccgaccggt tcagcggatc tagctctggc gccgaccgct acctgatcat ccccagcgtg     720
caggccgatg acgaggccga ttactactgt ggcgccgact acatcggcgg ctacgtgttc     780
ggcggaggca cccagctgac cgtgaccggc aattggagcc acccgcagtt cgaaaaagga     840
ggtggaggtt caggtggtgg aggctctgag agcaagtacg gaccgccctg ccccccttgc     900
cctatgttct gggtgctggt ggtggtcgga ggcgtgctgg cctgctacag cctgctggtc     960
accgtggcct tcatcatctt ttgggtgaaa cggggcagaa agaaactcct gtatatattc    1020
aaacaaccat ttatgagacc agtacaaact actcaagagg aagatggctg tagctgccga    1080
tttccagaag aagaagaagg aggatgtgaa ctgagacctc ctcctgtgcc taatcctgac    1140
tacgagccca tccggaaggg ccagagagat ctgtactccg gcctgaacca gcggcggatt    1200
cgggtgaagt tcagcagaag cgccgacgcc cctgcctacc agcagggcca gaatcagctg    1260
tacaacgagc tgaacctggg cagaagggaa gagtacgacg tcctggataa gcggagaggc    1320
cgggaccctg agatgggcgg caagcctcgg cggaagaacc cccaggaagg cctgtataac    1380
gaactgcaga aagacaagat ggccgaggcc tacagcgaga tcggcatgaa gggcgagcgg    1440
aggcggggca agggccacga cggcctgtat cagggcctgt ccaccgccac caaggatacc    1500
tacgacgccc tgcacatgca ggccctgccc ccaaggctcg agggcggcgg agagggcaga    1560
ggaagtcttc taacatgcgg tgacgtggag gagaatcccg gccctaggat gcttctcctg    1620
gtgacaagcc ttctgctctg tgagttacca cacccagcat tcctcctgat cccacgcaaa    1680
gtgtgtaacg gaataggtat tggtgaattt aaagactcac tctccataaa tgctacgaat    1740
attaaacact tcaaaaactg cacctccatc agtggcgatc tccacatcct gccggtggca    1800
tttaggggtg actccttcac acatactcct cctctggatc cacaggaact ggatattctg    1860
aaaaccgtaa aggaaatcac agggtttttg ctgattcagg cttggcctga aaacaggacg    1920
gacctccatg cctttgagaa cctagaaatc atacgcggca ggaccaagca acatggtcag    1980
ttttctcttg cagtcgtcag cctgaacata acatccttgg gattacgctc cctcaaggag    2040
ataagtgatg gagatgtgat aatttcagga aacaaaaatt tgtgctatgc aaatacaata    2100
aactggaaaa aactgtttgg gacctccggt cagaaaacca aaattataag caacagaggt    2160
gaaaacagct gcaaggccac aggccaggtc tgccatgcct tgtgctcccc cgagggctgc    2220
tggggcccgg agcccaggga ctgcgtctct tgccggaatg tcagccgagg cagggaatgc    2280
gtggacaagt gcaaccttct ggagggtgag ccaagggagt ttgtggagaa ctctgagtgc    2340
atacagtgcc acccagagtg cctgcctcag gccatgaaca tcacctgcac aggacgggga    2400
ccagacaact gtatccagtg tgcccactac attgacggcc cccactgcgt caagacctgc    2460
ccggcaggag tcatgggaga aaacaacacc ctggtctgga agtacgcaga cgccggccat    2520
gtgtgccacc tgtgccatcc aaactgcacc tacggatgca ctgggccagg tcttgaaggc    2580
tgtccaacga atgggcctaa gatcccgtcc atcgccactg ggatggtggg ggccctcctc    2640
ttgctgctgg tggtggccct ggggatcggc ctcttcatgt ga                       2682

<210> 45
<211> 2760
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic construct sequence: GM-CSF leader_R12
      scFv_STII_(G4S)2_IgG4
      hinge_CD28tm_4-1BB_CD3epsilon_CD3zeta_T2A_GM-CSF
      leader_tEGFR

<400> 45
atgctgctgc tggtgacaag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atcccccagg aacagctcgt cgaaagcggc ggcagactgg tgacacctgg cggcagcctg     120
accctgagct gcaaggccag cggcttcgac ttcagcgcct actacatgag ctgggtccgc     180
caggcccctg gcaagggact ggaatggatc gccaccatct accccagcag cggcaagacc     240
tactacgcca cctgggtgaa cggacggttc accatctcca gcgacaacgc ccagaacacc     300
gtggacctgc agatgaacag cctgacagcc gccgaccggg ccacctactt ttgcgccaga     360
gacagctacg ccgacgacgg cgccctgttc aacatctggg gccctggcac cctggtgaca     420
atctctagcg gcggaggcgg atctggtggc ggaggaagtg gcggcggagg atctgagctg     480
gtgctgaccc agagcccctc tgtgtctgct gccctgggaa gccctgccaa gatcacctgt     540
accctgagca gcgcccacaa gaccgacacc atcgactggt atcagcagct gcagggcgag     600
gcccccagat acctgatgca ggtgcagagc gacggcagct acaccaagag gccaggcgtg     660
cccgaccggt tcagcggatc tagctctggc gccgaccgct acctgatcat ccccagcgtg     720
caggccgatg acgaggccga ttactactgt ggcgccgact acatcggcgg ctacgtgttc     780
ggcggaggca cccagctgac cgtgaccggc aattggagcc acccgcagtt cgaaaaagga     840
ggtggaggtt caggtggtgg aggctctgag agcaagtacg gaccgccctg ccccccttgc     900
cctatgttct gggtgctggt ggtggtcgga ggcgtgctgg cctgctacag cctgctggtc     960
accgtggcct tcatcatctt ttgggtgaaa cggggcagaa agaaactcct gtatatattc    1020
aaacaaccat ttatgagacc agtacaaact actcaagagg aagatggctg tagctgccga    1080
tttccagaag aagaagaagg aggatgtgaa ctgaagaacc ggaaggccaa ggccaagcct    1140
gtgacaagag gtgctggtgc tggcggcaga cagagaggcc agaacaaaga aagacctcct    1200
cctgtgccta atcctgacta cgagcccatc cggaagggcc agagagatct gtactccggc    1260
ctgaaccagc ggcggattcg ggtgaagttc agcagaagcg ccgacgcccc tgcctaccag    1320
cagggccaga atcagctgta caacgagctg aacctgggca gaagggaaga gtacgacgtc    1380
ctggataagc ggagaggccg ggaccctgag atgggcggca agcctcggcg gaagaacccc    1440
caggaaggcc tgtataacga actgcagaaa gacaagatgg ccgaggccta cagcgagatc    1500
ggcatgaagg gcgagcggag gcggggcaag ggccacgacg gcctgtatca gggcctgtcc    1560
accgccacca aggataccta cgacgccctg cacatgcagg ccctgccccc aaggctcgag    1620
ggcggcggag agggcagagg aagtcttcta acatgcggtg acgtggagga gaatcccggc    1680
cctaggatgc ttctcctggt gacaagcctt ctgctctgtg agttaccaca cccagcattc    1740
ctcctgatcc cacgcaaagt gtgtaacgga ataggtattg gtgaatttaa agactcactc    1800
tccataaatg ctacgaatat taaacacttc aaaaactgca cctccatcag tggcgatctc    1860
cacatcctgc cggtggcatt taggggtgac tccttcacac atactcctcc tctggatcca    1920
caggaactgg atattctgaa aaccgtaaag gaaatcacag ggtttttgct gattcaggct    1980
tggcctgaaa acaggacgga cctccatgcc tttgagaacc tagaaatcat acgcggcagg    2040
accaagcaac atggtcagtt ttctcttgca gtcgtcagcc tgaacataac atccttggga    2100
ttacgctccc tcaaggagat aagtgatgga gatgtgataa tttcaggaaa caaaaatttg    2160
tgctatgcaa atacaataaa ctggaaaaaa ctgtttggga cctccggtca gaaaaccaaa    2220
attataagca acagaggtga aaacagctgc aaggccacag gccaggtctg ccatgccttg    2280
tgctcccccg agggctgctg gggcccggag cccagggact gcgtctcttg ccggaatgtc    2340
agccgaggca gggaatgcgt ggacaagtgc aaccttctgg agggtgagcc aagggagttt    2400
gtggagaact ctgagtgcat acagtgccac ccagagtgcc tgcctcaggc catgaacatc    2460
acctgcacag gacggggacc agacaactgt atccagtgtg cccactacat tgacggcccc    2520
cactgcgtca agacctgccc ggcaggagtc atgggagaaa acaacaccct ggtctggaag    2580
tacgcagacg ccggccatgt gtgccacctg tgccatccaa actgcaccta cggatgcact    2640
gggccaggtc ttgaaggctg tccaacgaat gggcctaaga tcccgtccat cgccactggg    2700
atggtggggg ccctcctctt gctgctggtg gtggccctgg ggatcggcct cttcatgtga    2760

<210> 46
<211> 2760
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic construct sequence: GM-CSF leader_R12
      scFv_STII_(G4S)2_IgG4
      hinge_CD28tm_4-1BB_CD3zeta_CD3epsilon_T2A_GM-CSF
      leader_tEGFR

<400> 46
atgctgctgc tggtgacaag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atcccccagg aacagctcgt cgaaagcggc ggcagactgg tgacacctgg cggcagcctg     120
accctgagct gcaaggccag cggcttcgac ttcagcgcct actacatgag ctgggtccgc     180
caggcccctg gcaagggact ggaatggatc gccaccatct accccagcag cggcaagacc     240
tactacgcca cctgggtgaa cggacggttc accatctcca gcgacaacgc ccagaacacc     300
gtggacctgc agatgaacag cctgacagcc gccgaccggg ccacctactt ttgcgccaga     360
gacagctacg ccgacgacgg cgccctgttc aacatctggg gccctggcac cctggtgaca     420
atctctagcg gcggaggcgg atctggtggc ggaggaagtg gcggcggagg atctgagctg     480
gtgctgaccc agagcccctc tgtgtctgct gccctgggaa gccctgccaa gatcacctgt     540
accctgagca gcgcccacaa gaccgacacc atcgactggt atcagcagct gcagggcgag     600
gcccccagat acctgatgca ggtgcagagc gacggcagct acaccaagag gccaggcgtg     660
cccgaccggt tcagcggatc tagctctggc gccgaccgct acctgatcat ccccagcgtg     720
caggccgatg acgaggccga ttactactgt ggcgccgact acatcggcgg ctacgtgttc     780
ggcggaggca cccagctgac cgtgaccggc aattggagcc acccgcagtt cgaaaaagga     840
ggtggaggtt caggtggtgg aggctctgag agcaagtacg gaccgccctg ccccccttgc     900
cctatgttct gggtgctggt ggtggtcgga ggcgtgctgg cctgctacag cctgctggtc     960
accgtggcct tcatcatctt ttgggtgaaa cggggcagaa agaaactcct gtatatattc    1020
aaacaaccat ttatgagacc agtacaaact actcaagagg aagatggctg tagctgccga    1080
tttccagaag aagaagaagg aggatgtgaa ctgcgggtga agttcagcag aagcgccgac    1140
gcccctgcct accagcaggg ccagaatcag ctgtacaacg agctgaacct gggcagaagg    1200
gaagagtacg acgtcctgga taagcggaga ggccgggacc ctgagatggg cggcaagcct    1260
cggcggaaga acccccagga aggcctgtat aacgaactgc agaaagacaa gatggccgag    1320
gcctacagcg agatcggcat gaagggcgag cggaggcggg gcaagggcca cgacggcctg    1380
tatcagggcc tgtccaccgc caccaaggat acctacgacg ccctgcacat gcaggccctg    1440
cccccaagga agaaccggaa ggccaaggcc aagcctgtga caagaggtgc tggtgctggc    1500
ggcagacaga gaggccagaa caaagaaaga cctcctcctg tgcctaatcc tgactacgag    1560
cccatccgga agggccagag agatctgtac tccggcctga accagcggcg gattctcgag    1620
ggcggcggag agggcagagg aagtcttcta acatgcggtg acgtggagga gaatcccggc    1680
cctaggatgc ttctcctggt gacaagcctt ctgctctgtg agttaccaca cccagcattc    1740
ctcctgatcc cacgcaaagt gtgtaacgga ataggtattg gtgaatttaa agactcactc    1800
tccataaatg ctacgaatat taaacacttc aaaaactgca cctccatcag tggcgatctc    1860
cacatcctgc cggtggcatt taggggtgac tccttcacac atactcctcc tctggatcca    1920
caggaactgg atattctgaa aaccgtaaag gaaatcacag ggtttttgct gattcaggct    1980
tggcctgaaa acaggacgga cctccatgcc tttgagaacc tagaaatcat acgcggcagg    2040
accaagcaac atggtcagtt ttctcttgca gtcgtcagcc tgaacataac atccttggga    2100
ttacgctccc tcaaggagat aagtgatgga gatgtgataa tttcaggaaa caaaaatttg    2160
tgctatgcaa atacaataaa ctggaaaaaa ctgtttggga cctccggtca gaaaaccaaa    2220
attataagca acagaggtga aaacagctgc aaggccacag gccaggtctg ccatgccttg    2280
tgctcccccg agggctgctg gggcccggag cccagggact gcgtctcttg ccggaatgtc    2340
agccgaggca gggaatgcgt ggacaagtgc aaccttctgg agggtgagcc aagggagttt    2400
gtggagaact ctgagtgcat acagtgccac ccagagtgcc tgcctcaggc catgaacatc    2460
acctgcacag gacggggacc agacaactgt atccagtgtg cccactacat tgacggcccc    2520
cactgcgtca agacctgccc ggcaggagtc atgggagaaa acaacaccct ggtctggaag    2580
tacgcagacg ccggccatgt gtgccacctg tgccatccaa actgcaccta cggatgcact    2640
gggccaggtc ttgaaggctg tccaacgaat gggcctaaga tcccgtccat cgccactggg    2700
atggtggggg ccctcctctt gctgctggtg gtggccctgg ggatcggcct cttcatgtga    2760

<210> 47
<211> 41
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic CD28 intracellular amino acid sequence
      (LL to GG)

<400> 47
Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr
 1               5                  10                  15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
            20                  25                  30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
        35                  40

<210> 48
<211> 42
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic OX40 intracellular amino acid sequence

<400> 48
Ala Leu Tyr Leu Leu Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His
 1               5                  10                  15
Lys Pro Pro Gly Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln
            20                  25                  30
Ala Asp Ala His Ser Thr Leu Ala Lys Ile
        35                  40

<210> 49
<211> 38
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ICOS intracellular amino acid sequence

<400> 49
Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro Asn
 1               5                  10                  15
Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser Arg
            20                  25                  30
Leu Thr Asp Val Thr Leu
        35

<210> 50
<211> 22
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Porcine teschovirus-1 2A (P2A) peptide

<400> 50
Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val
 1               5                  10                  15
Glu Glu Asn Pro Gly Pro
            20

<210> 51
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Thoseaasigna virus 2A (T2A) peptide

<400> 51
Leu Glu Gly Gly Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp
 1               5                  10                  15
Val Glu Glu Asn Pro Gly Pro Arg
            20

<210> 52
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Equine rhinitis A virus (ERAV) 2A (E2A)
      peptide

<400> 52
Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu Ala Gly Asp Val Glu Ser
 1               5                  10                  15
Asn Pro Gly Pro
            20

<210> 53
<211> 25
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Foot-and-Mouth disease virus 2A (F2A)
      peptide

<400> 53
Gly Ser Gly Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala
 1               5                  10                  15
Gly Asp Val Glu Ser Asn Pro Gly Pro
            20                  25

<210> 54
<211> 335
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic tEGFR sequence

<400> 54
Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp Ser Leu
 1               5                  10                  15
Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr Ser Ile
            20                  25                  30
Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp Ser Phe
        35                  40                  45
Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp Ile Leu Lys Thr
    50                  55                  60
Val Lys Glu Ile Thr Gly Phe Leu Leu Ile Gln Ala Trp Pro Glu Asn
65                  70                  75                  80
Arg Thr Asp Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg Gly Arg
                85                  90                  95
Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val Val Ser Leu Asn Ile
            100                 105                 110
Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly Asp Val
        115                 120                 125
Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile Asn Trp
    130                 135                 140
Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile Ser Asn
145                 150                 155                 160
Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His Ala Leu
                165                 170                 175
Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys Val Ser
            180                 185                 190
Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu
        195                 200                 205
Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln
    210                 215                 220
Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly
225                 230                 235                 240
Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly Pro
                245                 250                 255
His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn Asn Thr
            260                 265                 270
Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys His Leu Cys His
        275                 280                 285
Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly Cys Pro
    290                 295                 300
Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val Gly Ala
305                 310                 315                 320
Leu Leu Leu Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met
                325                 330                 335

<210> 55
<211> 248
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic anti-ROR1 scFv

<400> 55
Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly
 1               5                  10                  15
Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe Ser Ala Tyr
            20                  25                  30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45
Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala Thr Trp Val
    50                  55                  60
Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn Thr Val Asp
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr Tyr Phe Cys
                85                  90                  95
Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn Ile Trp Gly
            100                 105                 110
Pro Gly Thr Leu Val Thr Ile Ser Ser Gly Gly Gly Gly Ser Gly Gly
        115                 120                 125
Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Leu Thr Gln Ser Pro
    130                 135                 140
Ser Val Ser Ala Ala Leu Gly Ser Pro Ala Lys Ile Thr Cys Thr Leu
145                 150                 155                 160
Ser Ser Ala His Lys Thr Asp Thr Ile Asp Trp Tyr Gln Gln Leu Gln
                165                 170                 175
Gly Glu Ala Pro Arg Tyr Leu Met Gln Val Gln Ser Asp Gly Ser Tyr
            180                 185                 190
Thr Lys Arg Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly
        195                 200                 205
Ala Asp Arg Tyr Leu Ile Ile Pro Ser Val Gln Ala Asp Asp Glu Ala
    210                 215                 220
Asp Tyr Tyr Cys Gly Ala Asp Tyr Ile Gly Gly Tyr Val Phe Gly Gly
225                 230                 235                 240
Gly Thr Gln Leu Thr Val Thr Gly
                245

<210> 56
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY CDRH1

<400> 56
Asp Tyr Pro Ile Ser
 1               5

<210> 57
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY CDRH2

<400> 57
Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp Val Lys Gly
 1               5                  10                  15

<210> 58
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY CDRH3

<400> 58
Gly Tyr Ser Thr Tyr Tyr Gly Asp Phe Asn Ile
 1               5                  10

<210> 59
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY CDRL1

<400> 59
Gln Ala Ser Gln Ser Ile Asp Ser Asn Leu Ala
 1               5                  10

<210> 60
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY CDRL2

<400> 60
Arg Ala Ser Asn Leu Ala Ser
 1               5

<210> 61
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY CDRL3

<400> 61
Leu Gly Gly Val Gly Asn Val Ser Tyr Arg Thr Ser
 1               5                  10

<210> 62
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY VH

<400> 62
Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Thr Pro Ala Gly Asn
 1               5                  10                  15
Leu Thr Leu Thr Cys Thr Ala Ser Gly Ser Asp Ile Asn Asp Tyr Pro
            20                  25                  30
Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
        35                  40                  45
Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp Val Lys Gly
    50                  55                  60
Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met Thr
65                  70                  75                  80
Ser Leu Thr Thr Asp Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Tyr
                85                  90                  95
Ser Thr Tyr Tyr Gly Asp Phe Asn Ile Trp Gly Pro Gly Thr Leu Val
            100                 105                 110
Thr Ile Ser Ser
        115

<210> 63
<211> 110
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 ANTIBODY VL

<400> 63
Glu Leu Val Met Thr Gln Thr Pro Ser Ser Thr Ser Gly Ala Val Gly
 1               5                  10                  15
Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Ile Asp Ser Asn
            20                  25                  30
Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Thr Leu Leu Ile
        35                  40                  45
Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Arg Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Arg
65                  70                  75                  80
Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Val Gly Asn Val Ser
                85                  90                  95
Tyr Arg Thr Ser Phe Gly Gly Gly Thr Glu Val Val Val Lys
            100                 105                 110

<210> 64
<211> 241
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R11 SCFV

<400> 64
Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Thr Pro Ala Gly Asn
 1               5                  10                  15
Leu Thr Leu Thr Cys Thr Ala Ser Gly Ser Asp Ile Asn Asp Tyr Pro
            20                  25                  30
Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
        35                  40                  45
Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp Val Lys Gly
    50                  55                  60
Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met Thr
65                  70                  75                  80
Ser Leu Thr Thr Asp Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Tyr
                85                  90                  95
Ser Thr Tyr Tyr Gly Asp Phe Asn Ile Trp Gly Pro Gly Thr Leu Val
            100                 105                 110
Thr Ile Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
        115                 120                 125
Gly Gly Ser Glu Leu Val Met Thr Gln Thr Pro Ser Ser Thr Ser Gly
    130                 135                 140
Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Ile
145                 150                 155                 160
Asp Ser Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Thr
                165                 170                 175
Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg
            180                 185                 190
Phe Ser Gly Ser Arg Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly
        195                 200                 205
Val Gln Arg Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Val Gly
    210                 215                 220
Asn Val Ser Tyr Arg Thr Ser Phe Gly Gly Gly Thr Glu Val Val Val
225                 230                 235                 240
Lys


<210> 65
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Y31 ANTIBODY CD

<400> 65
Ser His Trp Met Ser
 1               5

<210> 66
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Y31 ANTIBODY CDRH2

<400> 66
Ile Ile Ala Ala Ser Gly Ser Thr Tyr Tyr Ala Asn Trp Ala Lys Gly
 1               5                  10                  15

<210> 67
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Y31 ANTIBODY CDRH3

<400> 67
Asp Tyr Gly Asp Tyr Arg Leu Val Thr Phe Asn Ile
 1               5                  10

<210> 68
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Y31 ANTIBODY CDRL1

<400> 68
Gln Ala Ser Gln Ser Ile Gly Ser Tyr Leu Ala
 1               5                  10

<210> 69
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Y31 ANTIBODY CDRL2

<400> 69
Tyr Ala Ser Asn Leu Ala Ser
 1               5

<210> 70
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Y31 ANTIBODY CDRL3

<400> 70
Leu Gly Ser Leu Asn Ser Asp Asn Val
 1               5

<210> 71
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY CDRH1

<400> 71
Asp Tyr Glu Met His
 1               5

<210> 72
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY CDRH2

<400> 72
Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15
Gly


<210> 73
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY CDRH3

<400> 73
Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr
 1               5

<210> 74
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY CDRL1

<400> 74
Lys Ala Ser Gln Asn Val Asp Ala Ala Val Ala
 1               5                  10

<210> 75
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY CDRL2

<400> 75
Ser Ala Ser Asn Arg Tyr Thr
 1               5

<210> 76
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY CDRL3

<400> 76
Gln Gln Tyr Asp Ile Tyr Pro Tyr Thr
 1               5

<210> 77
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY VH

<400> 77
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
 1               5                  10                  15
Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr
            20                  25                  30
Glu Met His Trp Val Ile Gln Thr Pro Val His Gly Leu Glu Trp Ile
        35                  40                  45
Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
    50                  55                  60
Lys Gly Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95
Thr Gly Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr
            100                 105                 110
Leu Val Thr Val Ser Ala
        115

<210> 78
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 ANTIBODY VL

<400> 78
Asp Ile Val Met Thr Gln Ser Gln Lys Ile Met Ser Thr Thr Val Gly
 1               5                  10                  15
Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Ala Ala
            20                  25                  30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
        35                  40                  45
Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser
65                  70                  75                  80
Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asp Ile Tyr Pro Tyr
                85                  90                  95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105

<210> 79
<211> 237
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic 2A2 SCFV

<400> 79
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
 1               5                  10                  15
Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr
            20                  25                  30
Glu Met His Trp Val Ile Gln Thr Pro Val His Gly Leu Glu Trp Ile
        35                  40                  45
Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
    50                  55                  60
Lys Gly Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95
Thr Gly Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr
            100                 105                 110
Leu Val Thr Val Ser Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly
        115                 120                 125
Gly Ser Asp Ile Val Met Thr Gln Ser Gln Lys Ile Met Ser Thr Thr
    130                 135                 140
Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Asp
145                 150                 155                 160
Ala Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu
                165                 170                 175
Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe
            180                 185                 190
Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met
        195                 200                 205
Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asp Ile Tyr
    210                 215                 220
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
225                 230                 235

<210> 80
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY CDRH1

<400> 80
Ala Tyr Tyr Met Ser
 1               5

<210> 81
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY CDRH2

<400> 81
Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala Thr Trp Val Asn
 1               5                  10                  15
Gly


<210> 82
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY CDRH3

<400> 82
Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn Ile
 1               5                  10

<210> 83
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY CDRL1

<400> 83
Thr Leu Ser Ser Ala His Lys Thr Asp Thr Ile Asp
 1               5                  10

<210> 84
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY CDRL2

<400> 84
Gly Ser Tyr Thr Lys Arg Pro
 1               5

<210> 85
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY CDRL3

<400> 85
Gly Ala Asp Tyr Ile Gly Gly Tyr Val
 1               5

<210> 86
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY VH

<400> 86
Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly
 1               5                  10                  15
Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe Ser Ala Tyr
            20                  25                  30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45
Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala Thr Trp Val
    50                  55                  60
Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn Thr Val Asp
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr Tyr Phe Cys
                85                  90                  95
Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn Ile Trp Gly
            100                 105                 110
Pro Gly Thr Leu Val Thr Ile Ser Ser
        115                 120

<210> 87
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic R12 ANTIBODY VL

<400> 87
Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala Ala Leu Gly Ser
 1               5                  10                  15
Pro Ala Lys Ile Thr Cys Thr Leu Ser Ser Ala His Lys Thr Asp Thr
            20                  25                  30
Ile Asp Trp Tyr Gln Gln Leu Gln Gly Glu Ala Pro Arg Tyr Leu Met
        35                  40                  45
Gln Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro Gly Val Pro Asp
    50                  55                  60
Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr Leu Ile Ile Pro
65                  70                  75                  80
Ser Val Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Asp Tyr
                85                  90                  95
Ile Gly Gly Tyr Val Phe Gly Gly Gly Thr Gln Leu Thr Val Thr Gly
            100                 105                 110

<210> 88
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRH1

<400> 88
Asp Thr Ile Asp Trp Tyr
 1               5

<210> 89
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRH2

<400> 89
Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro Gly Val Pro Asp Arg
 1               5                  10                  15

<210> 90
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRH3

<400> 90
Tyr Ile Gly Gly Tyr Val Phe Gly
 1               5

<210> 91
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRL1

<400> 91
Ala Ser Gly Phe Asp Phe Ser Ala Tyr Tyr Met
 1               5                  10

<210> 92
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRL2

<400> 92
Thr Ile Tyr Pro Ser Ser Gly
 1               5

<210> 93
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRL3

<400> 93
Ala Asp Arg Ala Thr Tyr Phe Cys Ala
 1               5

<210> 94
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRH1

<400> 94
Ser Asn Leu Ala Trp
 1               5

<210> 95
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRH2

<400> 95
Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 1               5                  10                  15

<210> 96
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRH3

<400> 96
Asn Val Ser Tyr Arg Thr Ser Phe
 1               5

<210> 97
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRL1

<400> 97
Ser Gly Ser Asp Ile Asn Asp Tyr Pro Ile Ser
 1               5                  10

<210> 98
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRL2

<400> 98
Ile Asn Ser Gly Gly Ser Thr
 1               5

<210> 99
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-ROR1 SCFV CDRL3

<400> 99
Tyr Phe Cys Ala Arg Gly Tyr Ser
 1               5

<210> 100
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-CD19 FMC63 VL

<400> 100
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
            20                  25                  30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
                85                  90                  95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr
            100                 105

<210> 101
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-CD19 FMC63 VH

<400> 101
Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
 1               5                  10                  15
Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr
            20                  25                  30
Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu
        35                  40                  45
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
    50                  55                  60
Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
65                  70                  75                  80
Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                85                  90                  95
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln
            100                 105                 110
Gly Thr Ser Val Thr Val Ser Ser
        115                 120

<210> 102
<211> 245
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic ANTI-CD19 FMC63 SCFV

<400> 102
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
            20                  25                  30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
                85                  90                  95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr Ser Gly
            100                 105                 110
Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys
        115                 120                 125
Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser
    130                 135                 140
Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser
145                 150                 155                 160
Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile
                165                 170                 175
Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu
            180                 185                 190
Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn
        195                 200                 205
Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr
    210                 215                 220
Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
225                 230                 235                 240
Val Thr Val Ser Ser
                245

<210> 103
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker 218 amino acid sequence

<400> 103
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
 1               5                  10                  15
Lys Gly


<210> 104
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<400> 104
Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
 1               5                  10

<210> 105
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<400> 105
Gly Lys Pro Gly Ser Gly Glu Gly
 1               5

<210> 106
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<400> 106
Ser Gly Lys Pro Gly Ser Gly Glu
 1               5

<210> 107
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<220>
<221> VARIANT        
<222> 1
<223> Xaa = positively charged amino acid

<220>
<221> VARIANT        
<222> 3,4,5
<223> Xaa = Gly or Ser

<220>
<221> VARIANT        
<222> 6
<223> Xaa = Gly or negatively charged amino acid

<400> 107
Xaa Pro Xaa Xaa Xaa Xaa
 1               5

<210> 108
<211> 200
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<220>
<221> VARIANT        
<222> (1)...(200)
<223> any one or all of amino acids 2-10,  12-200 can
      either be  present or absent

<400> 108
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Ser
 1               5                  10                  15
Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser
            20                  25                  30
Ser Ser Ser Ser Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly
        35                  40                  45
Gly Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Gly Gly Gly Gly
    50                  55                  60
Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser
65                  70                  75                  80
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Ser
                85                  90                  95
Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser
            100                 105                 110
Ser Ser Ser Ser Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly
        115                 120                 125
Gly Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Gly Gly Gly Gly
    130                 135                 140
Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser
145                 150                 155                 160
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Ser
                165                 170                 175
Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser
            180                 185                 190
Ser Ser Ser Ser Ser Ser Ser Ser
        195                 200

<210> 109
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<400> 109
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10                  15

<210> 110
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic linker amino acid sequence

<400> 110
Gly Ser Thr Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly
 1               5                  10                  15
Ser Ser


<210> 111
<211> 55
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic human CD3epsilon cytoplasmic domain

<400> 111
Lys Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala Gly Ala
 1               5                  10                  15
Gly Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro Val Pro
            20                  25                  30
Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser
        35                  40                  45
Gly Leu Asn Gln Arg Arg Ile
    50                  55
